Abingworth

Abingworth is a prominent international life sciences investment group with a rich history spanning over five decades. Established in 1973, the firm has consistently focused on collaborating with entrepreneurs to build and grow leading companies within the life sciences sector. With offices strategically located in London, Menlo Park, and Boston, Abingworth maintains a global footprint, enabling it to identify and support innovative ventures across key biotechnology and pharmaceutical hubs. Their long-standing presence and deep industry expertise have positioned them as a significant player in the venture capital landscape dedicated to healthcare innovation.

The firm's investment strategy is notably broad, encompassing all stages of company development, from nascent seed rounds to mature late-stage financing. Abingworth's portfolio diversifies across various life sciences sectors, including therapeutics, medical devices, and diagnostics, reflecting a comprehensive approach to healthcare investment. Over its extensive history, Abingworth has successfully raised over $2 billion across multiple funds, demonstrating robust financial backing and investor confidence. This substantial capital base allows them to make meaningful investments and provide sustained support to their portfolio companies.

Abingworth typically deploys significant capital into its portfolio companies. While specific first check sizes can vary depending on the stage and needs of the company, their initial investments generally range from $5 million for early-stage opportunities to as much as $50 million for leading later-stage rounds. This flexibility allows them to be a versatile partner, capable of supporting companies from their foundational development through to commercialization. The firm has invested in over 185 life sciences companies, underscoring their prolific activity and commitment to fostering advancements in medical science. Their approach emphasizes active partnership, leveraging their extensive network and operational experience to guide companies towards successful outcomes, including strategic partnerships, IPOs, and M&A exits.